Last reviewed · How we verify
Pneumococcal polysaccharide vaccine
Pneumococcal polysaccharide vaccine stimulates the immune system to produce antibodies against multiple serotypes of Streptococcus pneumoniae, providing protection against pneumococcal infection.
Pneumococcal polysaccharide vaccine stimulates the immune system to produce antibodies against multiple serotypes of Streptococcus pneumoniae, providing protection against pneumococcal infection. Used for Prevention of invasive pneumococcal disease in adults ≥50 years, Prevention of pneumococcal pneumonia, bacteremia, and meningitis in at-risk populations, Immunization of patients with chronic conditions (COPD, cardiovascular disease, diabetes) and immunocompromised individuals.
At a glance
| Generic name | Pneumococcal polysaccharide vaccine |
|---|---|
| Also known as | PPSV23, PPV, Pneumo23/Pneumovax, Pneumo23®, Pneumovax |
| Sponsor | Celgene |
| Drug class | Polysaccharide vaccine |
| Target | Streptococcus pneumoniae capsular polysaccharides (23 serotypes) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains purified polysaccharide capsular antigens from 23 different serotypes of Streptococcus pneumoniae. When administered, these antigens trigger B-cell activation and antibody production (primarily IgG), which bind to pneumococcal polysaccharides and facilitate opsonization, complement activation, and phagocytic clearance of the bacteria. This provides immunity against invasive pneumococcal disease including pneumonia, bacteremia, and meningitis.
Approved indications
- Prevention of invasive pneumococcal disease in adults ≥50 years
- Prevention of pneumococcal pneumonia, bacteremia, and meningitis in at-risk populations
- Immunization of patients with chronic conditions (COPD, cardiovascular disease, diabetes) and immunocompromised individuals
Common side effects
- Injection site pain/erythema
- Myalgia
- Headache
- Fatigue
- Fever
- Local swelling
Key clinical trials
- Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs (PHASE4)
- A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002) (PHASE1)
- Nasopharyngeal Carriage of S. Pneumoniae (NA)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination (PHASE3)
- Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (PHASE2)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 (PHASE3)
- Safety and Efficacy of wSp Vaccine in Young Children (PHASE2)
- Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pneumococcal polysaccharide vaccine CI brief — competitive landscape report
- Pneumococcal polysaccharide vaccine updates RSS · CI watch RSS
- Celgene portfolio CI